MX2022008181A - Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. - Google Patents

Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.

Info

Publication number
MX2022008181A
MX2022008181A MX2022008181A MX2022008181A MX2022008181A MX 2022008181 A MX2022008181 A MX 2022008181A MX 2022008181 A MX2022008181 A MX 2022008181A MX 2022008181 A MX2022008181 A MX 2022008181A MX 2022008181 A MX2022008181 A MX 2022008181A
Authority
MX
Mexico
Prior art keywords
dementia
quinidine
agitation
treatment
pharmaceutical compositions
Prior art date
Application number
MX2022008181A
Other languages
English (en)
Inventor
Joao Siffert
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Publication of MX2022008181A publication Critical patent/MX2022008181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se relaciona a métodos para tratar agitación y/o agresión y/o síntomas asociados en sujetos con demencia, incluyendo, demencia asociada con la enfermedad de Alzheimer. El método incluye administrar a un sujeto en necesidad del mismo un compuesto de dextrometorfano, o una sal farmacéuticamente aceptable del mismo, en combinación con quinidina, o una sal farmacéuticamente aceptable de la misma. La descripción en ciertos aspectos también se relaciona a composiciones que se utilizan para tratar agitación y/o agresión y/o síntomas asociados en sujetos que sufren de enfermedad de Alzheimer.
MX2022008181A 2014-09-14 2017-03-08 Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. MX2022008181A (es)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201462050170P 2014-09-14 2014-09-14
US201462061451P 2014-10-08 2014-10-08
US201462063122P 2014-10-13 2014-10-13
US201462063861P 2014-10-14 2014-10-14
US201462068742P 2014-10-26 2014-10-26
US201562111053P 2015-02-02 2015-02-02
US201562111590P 2015-02-03 2015-02-03
US201562128446P 2015-03-04 2015-03-04
US201562162140P 2015-05-15 2015-05-15
US201562165535P 2015-05-22 2015-05-22
US201562169997P 2015-06-02 2015-06-02
US201562180026P 2015-06-15 2015-06-15
US201562193347P 2015-07-16 2015-07-16
US201562205061P 2015-08-14 2015-08-14
US201562216636P 2015-09-10 2015-09-10
US201562217142P 2015-09-11 2015-09-11
US201562217470P 2015-09-11 2015-09-11

Publications (1)

Publication Number Publication Date
MX2022008181A true MX2022008181A (es) 2022-08-10

Family

ID=55459653

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017003066A MX2017003066A (es) 2014-09-14 2015-09-14 Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.
MX2021010696A MX2021010696A (es) 2014-09-14 2017-03-08 Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.
MX2022008181A MX2022008181A (es) 2014-09-14 2017-03-08 Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017003066A MX2017003066A (es) 2014-09-14 2015-09-14 Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.
MX2021010696A MX2021010696A (es) 2014-09-14 2017-03-08 Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.

Country Status (14)

Country Link
US (3) US20190111047A1 (es)
EP (4) EP4166141A1 (es)
JP (4) JP2017531033A (es)
KR (1) KR20170052684A (es)
CN (3) CN110664801A (es)
AU (3) AU2015314710A1 (es)
CA (1) CA2960031A1 (es)
IL (2) IL250786A0 (es)
MX (3) MX2017003066A (es)
PH (1) PH12017500444A1 (es)
RU (2) RU2020116666A (es)
SG (2) SG10201901242PA (es)
TW (3) TW202231278A (es)
WO (1) WO2016040930A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146412A1 (en) * 2019-01-07 2020-07-16 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US20180243289A1 (en) * 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020014A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
EP4122919A1 (en) * 2016-07-04 2023-01-25 Avanir Pharmaceuticals, Inc. Methods for the synthesis of deuterated dextromethorphan
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
EP3941469A4 (en) * 2019-03-18 2022-05-18 Avanir Pharmaceuticals, Inc. METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTTERATED DEXTROMETHORPHANE AND QUINIDINE
EP4142729A1 (en) * 2020-04-27 2023-03-08 Avanir Pharmaceuticals, Inc. Methods of treating agitation associated with alzheimer's disease
CN115245515A (zh) * 2021-04-27 2022-10-28 杭州剂泰医药科技有限责任公司 一种组合物的医药用途
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
CN113209042A (zh) * 2021-05-28 2021-08-06 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法
WO2023076414A1 (en) * 2021-10-27 2023-05-04 Avanir Pharmaceuticals, Inc. Methods of treating agitation associated with alzheimer's disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
TW264473B (es) * 1993-01-06 1995-12-01 Hoffmann La Roche
WO1996009044A1 (en) * 1994-09-22 1996-03-28 Richard Alan Smith Compositions useful for the preparation of medicines for treating a variety of intractable disorders
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AU749214C (en) 1997-11-21 2006-03-30 Purdue Neuroscience Company Substituted 2-aminoacetamides and the use thereof
ID26031A (id) 1998-03-26 2000-11-16 Shionogi & Co Turunan indol yang memiliki suatu aktivitas antiviral
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
MX2008009947A (es) * 2006-02-03 2008-10-20 Avanir Pharmaceuticals Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
WO2007103474A2 (en) * 2006-03-07 2007-09-13 University Of Florida Research Foundation, Inc. Drug adherence monitoring system
WO2008097924A2 (en) * 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX370608B (es) * 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
EP2357183B1 (en) * 2007-05-01 2015-07-01 Concert Pharmaceuticals Inc. Morphinan compounds
DK3248978T3 (da) * 2008-09-19 2019-11-18 Concert Pharmaceuticals Inc Deutererede morphinanforbindelser
PL2397158T3 (pl) * 2008-10-30 2016-09-30 Skojarzone podawanie związków morfinanów oraz leków przeciwdepresyjnych w leczeniu nietrzymania afektu
MX2011005112A (es) * 2008-11-14 2011-06-16 Concert Pharmaceuticals Inc Derivados de dioxopiperidinil-ftalimida sustituida.
NZ758431A (en) * 2013-11-05 2021-07-30 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Also Published As

Publication number Publication date
EP3708168A2 (en) 2020-09-16
AU2020289733A1 (en) 2021-01-21
JP7360409B2 (ja) 2023-10-12
RU2017112747A (ru) 2018-10-15
SG10201901242PA (en) 2019-03-28
CN117427077A (zh) 2024-01-23
IL274742A (en) 2020-07-30
JP2021080300A (ja) 2021-05-27
PH12017500444A1 (en) 2017-07-31
TW201613591A (en) 2016-04-16
US20200289499A1 (en) 2020-09-17
EP4166141A1 (en) 2023-04-19
MX2021010696A (es) 2021-10-01
CN110664801A (zh) 2020-01-10
TW202106301A (zh) 2021-02-16
CN107072990A (zh) 2017-08-18
AU2022283671A1 (en) 2023-02-02
JP2020019818A (ja) 2020-02-06
RU2017112747A3 (es) 2019-04-29
TW202231278A (zh) 2022-08-16
US20240082237A1 (en) 2024-03-14
EP3708168A3 (en) 2020-12-09
US20190111047A1 (en) 2019-04-18
IL250786A0 (en) 2017-04-30
AU2015314710A1 (en) 2017-04-20
EP3193872A4 (en) 2018-02-28
EP3932907A2 (en) 2022-01-05
KR20170052684A (ko) 2017-05-12
JP2017531033A (ja) 2017-10-19
CA2960031A1 (en) 2016-03-17
SG11201701645WA (en) 2017-04-27
WO2016040930A1 (en) 2016-03-17
JP2023105265A (ja) 2023-07-28
MX2017003066A (es) 2017-09-12
EP3193872A1 (en) 2017-07-26
EP3932907A3 (en) 2022-03-30
RU2020116666A (ru) 2020-07-31

Similar Documents

Publication Publication Date Title
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2021009673A (es) Moduladores de ror-gamma.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
IN2015DN00376A (es)
EA201791993A1 (ru) Способы лечения протеинопатий
TW201613636A (en) Methods of treating Alzheimer's Disease
MX2019014711A (es) Polimeros de union a protones para administracion oral.
MX2021002321A (es) Nuevos metodos.
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
WO2016122289A3 (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2016008968A (es) Compuestos organicos.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
SG10201809280PA (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен